The FDA announced Medtronic has issued a recall of its implantable cardioverter defibrillators and cardiac resynchronization therapy devices due to a short circuit protection alert resulting in ...

CARE-HF is the first study to show benefit for CRT with respect to survival as a sole endpoint, and is also the first to show benefit and continued improvement over a long follow-up period.

Researchers determined that for patients in the RAFT trial, implanting a cardiac resynchronization therapy defibrillator, as opposed to an implantable cardioverter defibrillator, is cost-effective ...